-
AnnJi Pharma Signs USD 250 Million Licensing Deal with Avenue Therapeutics for Kennedy’s Disease Drug
•
Taiwan-based AnnJi Pharmaceutical Co., Ltd has announced the signing of a licensing agreement with US firm Avenue Therapeutics Inc. (NASDAQ: ATXI) for its innovative small-molecule drug candidate AJ201, targeting the rare Kennedy’s disease. Under the agreement, AnnJi Pharma will receive up to USD 250 million in licensing fees, including an…
